even in the low viremic phase. Hepatitis B e antigen seroconversion with hepatitis B virus (HBV) DNA levels just below 10 5 copies/mL may not be an adequate treatment endpoint for Asian CHB patients.

Candidates for antiviral therapy include those who are in the immune clearance (hepatitis B e antigen [HBeAg]-positive) or reactivation (HBeAg-negative) phases. Hepatitis B & hepatocellular ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

"GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

Twenty-seven patients with Chronic Hepatitis B Virus infection (CHB ... intramuscular (i.m.) injection VRON-0200 is a Phase 1b, multi-center, open-label, dose escalation, prime only, and prime ...